Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565255 | 0.94 | MAPT (0.49) | MAPTHSD17B10FAAHMCL1TSHR | |
| SCHEMBL20263717 | 0.88 | MAPT (0.56) | MAPTHSD17B10FAAHMCL1TSHR | |
| SCHEMBL20263728 | 0.88 | MAPT (0.56) | MAPTHSD17B10FAAHMCL1TSHR | |
| SCHEMBL5049817 | 0.82 | FAAH (0.47) | MAPTHSD17B10FAAHTSHRSELP | |
| SCHEMBL13257422 | 0.81 | MAPT (0.54) | MAPTHSD17B10FAAHMCL1TSHR | |
| SCHEMBL20263716 | 0.81 | MAPT (0.50) | MAPTHSD17B10FAAHMCL1TSHR | |
| SCHEMBL20263727 | 0.81 | MAPT (0.50) | MAPTHSD17B10FAAHMCL1TSHR | |
| SCHEMBL2564097 | 0.80 | FAAH (0.48) | MAPTHSD17B10FAAHMCL1TSHR | |
| SCHEMBL2569086 | 0.80 | FAAH (0.44) | MAPTFAAHMCL1TSHR | |
| SCHEMBL8108657 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382218-A1 | DELTA-5-DESATURASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010087467-A1 | DELTA-5-DESATURASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | MAPT 2366/4885HSD17B10 105/4885FAAH 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.